Type 2 diabetes
Conditions
Interventions
Oral administration of 100 mg Canagliflozin once a day after breakfast for 24 weeks
Sponsors
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
Nagoya City East Medical Center Nagoya City West Medical Center Kariya Toyota General Hospital Chita Kosei Hospital Asahi Rousai Hospital Toyokawa City Hospital Nishitita General Hospital Takahashi Family Clinic Okouchi Internal Medicine Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients under diet therapy and exercise 2. Patients without medicine or with under 2 types of diabetic medicines for 2 months except for an another SGLT2 inhibitor 3. HbA1c (NGSP) over 7.0 % or under 10 % 4. Patients who can understand the study and agree with the study by the document
Exclusion criteria
Exclusion criteria: 1. Patients with an allergy to Canagliflozin 2. Patients with diabetic ketoacidosis, diabetic coma and type 1 diabetes 3. Patients with over 2 times from upper limit of normal ranges of AST, ALT, or gamma-GTP 4. Patients with under 45 ml/min/1.73m2 of eGFR 5. Patients with severe inflammation or injury, or before or after operation 6. Patients with cancer or inflammatory bowel disease, or after operation of GI tracts 7. Patients with pregnancy or during lactation 8. Patients who are thought to be unsuitable for the study by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes of the hormones regulating appetite (active ghrelin and PYY) after 12 weeks from start of administrating of Canagliflozin | — |
Countries
Japan
Contacts
Public ContactNaotsuka Okayama
Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism
Outcome results
None listed